Alex Azar

Alex Michael Azar II is an American attorney and former business executive who served as the 24th United States Secretary of Health and Human Services from 2018 to 2021. Prior to his cabinet appointment, he held senior positions in both government legal affairs and the pharmaceutical industry, including a decade‑long tenure at Eli Lilly & Co. where he oversaw U.S. operations and later served as chairman of the White House Coronavirus Task Force during the early months of the COVID‑19 pandemic.

Early life and career

Azar was born on June 17, 1967, in Johnstown, Pennsylvania. He grew up in Salisbury, Maryland, the son of Lynda (Zarisky) Azar and Alex Michael Azar Sr., a retired ophthalmologist who practiced for more than three decades at Johns Hopkins Hospital. His paternal grandfather emigrated from Lebanon in the early twentieth century, and the family traces its roots to Amioun.

He attended Parkside High School in Salisbury, graduating in 1985. After high school he enrolled at Dartmouth College, where he earned a Bachelor of Arts degree summa cum laude in government and economics in 1988. While an undergraduate he joined the Kappa Kappa Kappa fraternity. Azar then pursued legal studies at Yale Law School, receiving his Juris Doctor in 1991. During law school he served on the executive committee of the Yale Law Journal.

Following graduation, Azar entered a series of prestigious clerkships. He first clerked for Judge Alex Kozinski of the United States Court of Appeals for the Ninth Circuit, though his tenure was brief; he subsequently completed the remainder of that term with Judge J. Michael Luttig of the Fourth Circuit. In 1993 he served as a law clerk to Associate Justice Antonin Scalia on the U.S. Supreme Court.

From 1994 to 1996 Azar worked as an associate independent counsel for Ken Starr in the Office of the Independent Counsel, contributing to the early stages of the Whitewater investigation. He then joined the Washington, D.C., law firm Wiley Rein, where he became a partner by 2001.

Cabinet tenure

Azar’s first major government role came on August 3, 2001, when he was confirmed as general counsel for the Department of Health and Human Services (HHS). In that capacity he helped shape the department’s response to the anthrax attacks of 2001, coordinated efforts related to smallpox vaccine readiness, and addressed outbreaks of SARS and influenza. On July 22, 2005, he advanced to deputy secretary of HHS, a position he held until his resignation in January 2007. As deputy secretary, Azar supervised day‑to‑day operations for an agency that would grow to manage an annual budget exceeding one trillion dollars by the time he later became secretary. His responsibilities included approving regulations, fostering global pharmaceutical and medical device innovation, and implementing performance improvement initiatives launched during the Bush administration.

In 2007 Azar transitioned to the private sector, joining Eli Lilly & Co. as senior vice president of corporate affairs and communications. He served in that role until 2009, when he became vice president of Lilly’s U.S. Managed Healthcare Services organization and its Puerto Rico affiliate. In January 2012 he was appointed president of Lilly USA, LLC, the company’s largest division, where he oversaw all domestic operations. During his tenure drug pricing increased significantly; for example, the price of the company’s insulin product rose markedly, a change that later became part of a class‑action lawsuit alleging exploitation of the U.S. drug‑pricing system. Eli Lilly also faced regulatory scrutiny abroad, including a fine in Mexico related to insulin pricing practices.

Azar remained with Eli Lilly until January 2017, when he resigned amid a corporate reorganization and stepped down from his board seat at the Biotechnology Innovation Organization, a pharmaceutical trade association. His departure was described as a move “to pursue other career opportunities.”

On November 13, 2017, President Donald Trump announced that Azar would be nominated for secretary of HHS. After Senate confirmation, he served in that role from 2018 until 2021. During his tenure he chaired the White House Coronavirus Task Force from its inception on January 29, 2020, until February 26, 2020, when Vice President Mike Pence succeeded him. In addition to pandemic‑related duties, Azar managed a broad portfolio that included Medicare and Medicaid programs, public health initiatives, and federal health research agencies.

Following the conclusion of his cabinet service in 2021, Azar accepted an academic appointment as senior executive in residence at the Herbert Business School of the University of Miami. In this capacity he engages with students and faculty on topics related to business leadership and public policy.

Legacy

Azar’s career spans significant legal, governmental, corporate, and educational roles that have shaped U.S. health policy over several decades. As general counsel and later deputy secretary of HHS, he contributed to the department’s preparedness for bioterrorism threats and infectious disease outbreaks, while also guiding regulatory frameworks that influence pharmaceutical development worldwide.

His decade at Eli Lilly placed him at the center of discussions about drug pricing and market dynamics. The increases in insulin costs under his leadership became a focal point in broader debates over affordability and access to essential medicines. These experiences informed his later work as secretary of HHS, where he oversaw programs affecting millions of Americans.

During the early phase of the COVID‑19 pandemic, Azar’s role on the White House Coronavirus Task Force positioned him at the forefront of national coordination efforts. Although his tenure in that specific capacity was brief, it underscored the importance of interagency collaboration during public health emergencies.

In addition to policy and regulatory work, Azar has contributed to academic discourse through his position at the University of Miami’s Herbert Business School. His involvement in education reflects a continued commitment to shaping future leaders in business and public service.

Overall, Alex Azar’s professional journey illustrates a blend of legal expertise, executive management, and public‑service leadership. His impact on health policy, drug regulation, and crisis response continues to be examined by scholars, policymakers, and industry stakeholders alike.